Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Actinium Pharmaceuticals Inc (ATNM)

Actinium Pharmaceuticals Inc (ATNM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 238,860
  • Shares Outstanding, K 29,783
  • Annual Sales, $ 80 K
  • Annual Income, $ -48,820 K
  • 60-Month Beta 0.12
  • Price/Sales 2,915.79
  • Price/Cash Flow N/A
  • Price/Book 5.39
Trade ATNM with:

Options Overview Details

View History
  • Implied Volatility 111.68% ( +26.13%)
  • Historical Volatility 54.34%
  • IV Percentile 87%
  • IV Rank 54.13%
  • IV High 167.63% on 01/18/24
  • IV Low 45.66% on 09/27/23
  • Put/Call Vol Ratio 0.01
  • Today's Volume 117
  • Volume Avg (30-Day) 217
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 6,413
  • Open Int (30-Day) 6,318

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.48
  • Number of Estimates 2
  • High Estimate -0.38
  • Low Estimate -0.58
  • Prior Year -0.58
  • Growth Rate Est. (year over year) +17.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.75 +0.90%
on 06/14/24
10.14 -22.88%
on 05/15/24
-2.07 (-20.93%)
since 05/14/24
3-Month
6.16 +26.95%
on 03/15/24
10.24 -23.63%
on 05/14/24
+1.55 (+24.72%)
since 03/14/24
52-Week
4.00 +95.50%
on 11/28/23
10.24 -23.63%
on 05/14/24
-0.14 (-1.76%)
since 06/14/23

Most Recent Stories

More News
Actinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual Meeting

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today...

ATNM : 7.82 (-2.49%)
Actinium Pharma Highlights Six Abstracts Accepted for Oral and Poster Presentation at the SNMMI 2023 Annual Meeting

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today...

ATNM : 7.82 (-2.49%)
Actinium Pharma to Present at the Maxim Healthcare Virtual Conference

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today...

ATNM : 7.82 (-2.49%)
Actinium Pharma Set to Join Russell 2000® and Russell 3000® Indexes

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today...

ATNM : 7.82 (-2.49%)
Actinium Pharma Announces Six Abstracts Accepted for Oral and Poster Presentation at the SNMMI 2023 Annual Meeting, Demonstrating Actinium's Leadership in Targeted Radiotherapy for Hematologic and Solid Cancers

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today...

ATNM : 7.82 (-2.49%)
Actinium Pharma Announces Iomab-B SIERRA Trial Results Accepted for Oral Presentation at the European Hematology Association 2023 Congress (EHA)

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today...

ATNM : 7.82 (-2.49%)
Actinium Pharma to Present at Guggenheim Healthcare Talks Radiopharmaceuticals Day

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today...

ATNM : 7.82 (-2.49%)
Coya Therapeutics Strengthens Leadership Team with Addition of Arun Swaminathan, Ph.D. as Chief Business Officer

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including...

ATNM : 7.82 (-2.49%)
COYA : 7.20 (-7.46%)
Global Market for Acute Myeloid Leukemia Expected to Reach $3.2 Billion By 2029

EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:AZN),(NYSE:BMY),(NYSE:AMAM),(NYSE:GSK) EQNX::TICKER_END

ATNM : 7.82 (-2.49%)
AMAM : 28.00 (+0.07%)
BMY : 41.20 (-0.68%)
AZN : 79.59 (+0.08%)
GSK : 40.65 (-1.12%)
Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia

– Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical significance (p-value of

ATNM : 7.82 (-2.49%)

Business Summary

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application for their ARCs is targeted conditioning, which is intended...

See More

Key Turning Points

3rd Resistance Point 8.36
2nd Resistance Point 8.23
1st Resistance Point 8.02
Last Price 7.82
1st Support Level 7.68
2nd Support Level 7.55
3rd Support Level 7.34

See More

52-Week High 10.24
Fibonacci 61.8% 7.86
Last Price 7.82
Fibonacci 50% 7.12
Fibonacci 38.2% 6.38
52-Week Low 4.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar